UNSPSC 51313414: Thenyldiamine

This classification denotes a histamine-1 receptor antagonist with the molecular formula C14H19N3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier E4U52363JE, chemically known as 1,2-ethanediamine, n,n-dimethyl-n-2-pyridinyl-n-(3-thienylmethyl)- but generally known as thenyldiamine, which bears US NIH Compound Identifier 7066. European Medicines Agency schedules Thenyldiamine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10962MIG.

UNSPSC 51313414 Thenyldiamine is a Commodity code that in practice encompasses naloxone, safe drug deactivation systems, and generic multi-source pharmaceuticals and over-the-counter products procured by state and local health and human services agencies. State and local governments buy these products primarily through competitive bidding (IFB), requests for information (RFI), and cooperative purchasing agreements to support community health initiatives, pharmacy benefit programs, and facility-based medical supply needs. Issuing bodies include county health departments, state HHS commissions, and multi-state cooperative purchasing alliances that aggregate demand across participating jurisdictions. The work involves procurement of finished pharmaceutical products and related harm-reduction supplies with defined specifications, NDC codes, dosage forms, and compliance certifications rather than manufacturing or chemical synthesis.

Recent activity spans Florida, Texas, and Minnesota. Seminole County, Florida posted IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries, response due July 26, 2023. The Texas Health and Human Services Commission issued RFI HHS0017013 on April 3, 2026, to gather vendor capabilities for direct-to-manufacturer prescription fulfillment programs outside traditional PBM and GPO channels. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, issued RFP S1070000015802 on January 20, 2026, to establish multiple contracts for generic pharmaceuticals and OTC products distributed across participating state and local facilities including Oregon, with proposals due March 26, 2026. Vendors responding to pharmaceutical procurements must certify cGMP and Drug Supply Chain Security Act compliance, maintain relationships with authorized wholesalers, and meet insurance and shelf-life requirements.